SANASana Biotechnology, Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−33% vs 200-day) and heavily shorted (+13% of shares).
In a downtrend, below its 50- and 200-day averages. Oversold (RSI 26). Price is −33% vs its 200-day average.
Heavily shorted, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How SANA is trading
Sana Biotechnology, Inc. is −58% over the past year while the S&P 500 is +16%: 74 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −33%
vs 200-day average · a clear downtrend
- RSI (14)
- 26
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 58%
Below its 52-week high
Details›
- Last close2026-10-23
- $2.33
- 1 monthS&P 500 −0.94%
- −21%
- 1 yearS&P 500 +16%
- −58%
- 5 yearsS&P 500 +86%
- −89%
- vs 50-day average$3.16
- −26%
- 52-week high
- $5.59
- 52-week low
- $2.27
- Annualised volatility
- 149%
| Year | Return |
|---|---|
| 2026 (year to date) | −43% |
| 2025 | +150% |
| 2024 | −60% |
| 2023 | +3.3% |
| 2022 | −74% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 4 of 5 | +23% |
| Feb | 5 | 1 of 5 | +2.6% |
| Mar | 6 | 2 of 6 | −7.0% |
| Apr | 6 | 3 of 6 | +5.8% |
| May | 6 | 3 of 6 | −3.8% |
| Jun | 6 | 3 of 6 | +3.7% |
| Jul | 6 | 3 of 6 | +5.9% |
| Aug | 6 | 3 of 6 | +6.5% |
| Sep | 6 | 1 of 6 | −14% |
| Oct | 6 | 1 of 6 | −5.2% |
| Nov | 5 | 1 of 5 | −3.8% |
| Dec | 5 | 1 of 5 | −17% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.